D J Cohen

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin
    David J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Cardiol 89:61-4. 2002
  2. ncbi request reprint Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial
    D J Cohen
    Harvard Clinical Research Institute and the Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am Heart J 142:648-56. 2001
  3. ncbi request reprint Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?
    D J Cohen
    Harvard Clinical Research Institute, Harvard Medical School, Boston, MA, USA
    Circulation 104:773-8. 2001
  4. ncbi request reprint Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories
    D J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Cardiol 86:595-601. 2000
  5. ncbi request reprint Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
    Circulation 108:2857-63. 2003
  6. ncbi request reprint A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
  7. doi request reprint In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry
    Victor Novack
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 2:767-75. 2009
  8. ncbi request reprint Coronary artery stenting in the aged
    M S Chauhan
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 37:856-62. 2001
  9. ncbi request reprint Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials
    Deborah A Taira
    Harvard Clinical Research Institute, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston 02215, USA
    Am Heart J 145:452-8. 2003
  10. ncbi request reprint Can we afford to eliminate restenosis? Can we afford not to?
    Dan Greenberg
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 43:513-8. 2004

Collaborators

Detail Information

Publications96

  1. ncbi request reprint In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin
    David J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Cardiol 89:61-4. 2002
  2. ncbi request reprint Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial
    D J Cohen
    Harvard Clinical Research Institute and the Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am Heart J 142:648-56. 2001
    ..Recently, rheolytic thrombectomy with the AngioJet device has been shown to safely remove intracoronary thrombus, but the overall cost-effectiveness of this technique is unknown...
  3. ncbi request reprint Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker's paradox?
    D J Cohen
    Harvard Clinical Research Institute, Harvard Medical School, Boston, MA, USA
    Circulation 104:773-8. 2001
    ..Recent studies have suggested that smokers may require less frequent repeated revascularization after percutaneous coronary intervention (PCI) compared with nonsmokers. However, the mechanism of this phenomenon is unknown...
  4. ncbi request reprint Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories
    D J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Cardiol 86:595-601. 2000
    ..These findings may be useful in defining specific time and cost benchmarks for these commonly performed procedures and serve to underscore the critical role of reducing complications in both quality improvement and cost-saving efforts...
  5. ncbi request reprint Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
    Circulation 108:2857-63. 2003
    ..Both stenting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing primary angioplasty for acute myocardial infarction (AMI). However, the cost-effectiveness of these strategies is unknown...
  6. ncbi request reprint A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
    ....
  7. doi request reprint In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry
    Victor Novack
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 2:767-75. 2009
    ..The aim of this study was to compare outcomes among unselected patients undergoing percutaneous coronary intervention (PCI) with either sirolimus-eluting (SES) or paclitaxel-eluting stents (PES)...
  8. ncbi request reprint Coronary artery stenting in the aged
    M S Chauhan
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 37:856-62. 2001
    ..The study compared the safety and efficacy of coronary artery stenting in aged and nonaged patients and identified predictors of adverse clinical outcomes...
  9. ncbi request reprint Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials
    Deborah A Taira
    Harvard Clinical Research Institute, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston 02215, USA
    Am Heart J 145:452-8. 2003
    ..We compared methods for measuring costs from multicenter clinical trials to determine the extent to which the methodology affects results...
  10. ncbi request reprint Can we afford to eliminate restenosis? Can we afford not to?
    Dan Greenberg
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 43:513-8. 2004
    ....
  11. ncbi request reprint Rheolytic thrombectomy and platelet glycoprotein IIb/IIIa blockade for stent thrombosis
    Stephane Rinfret
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Catheter Cardiovasc Interv 57:24-30. 2002
    ..A combined approach of rheolytic thrombectomy with adjunctive GP IIb/IIIa blockade was highly effective in resolving stent thrombosis and was associated with favorable acute and long-term outcomes...
  12. ncbi request reprint Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials
    H L Dauerman
    Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Catheter Cardiovasc Interv 49:237-43. 2000
    ..Cathet. Cardiovasc. Intervent. 49:237-243, 2000...
  13. ncbi request reprint Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
    ..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)...
  14. ncbi request reprint Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    Duane S Pinto
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Catheter Cardiovasc Interv 58:65-8. 2003
    ..In selected patients with HIT, the combination of a direct thrombin inhibitor, lepirudin, and abciximab, tirofiban, or eptifibatide appears to be a safe and effective anticoagulation strategy for PCI...
  15. ncbi request reprint Effectiveness of rheolytic coronary thrombectomy with the AngioJet catheter
    Stephane Rinfret
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Cardiol 90:470-6. 2002
    ..In-hospital and long-term clinical outcomes were favorable. Thus, rheolytic thrombectomy resulted in significant reduction of the thrombus burden in most patients, restored TIMI-3 flow, and led to favorable short- and long-term outcomes...
  16. ncbi request reprint Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 48:253-61. 2006
    ....
  17. ncbi request reprint Economic implications of bivalirudin in the cardiac catheterization laboratory
    Ameet Bakhai
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    Rev Cardiovasc Med 7:S35-42. 2006
    ..Whether these benefits can be extended to higher risk patient subsets including patients with non-ST elevation or ST elevation myocardial infarction is currently under investigation...
  18. ncbi request reprint Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 97:1473-7. 2006
    ..In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non-ST-elevation acute coronary syndrome...
  19. ncbi request reprint Current clinical characteristics and economic impact of subacute stent thrombosis
    Matthew R Reynolds
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Invasive Cardiol 14:364-8. 2002
    ..Conclusions. Despite its low overall frequency, the clinical and economic costs of SAT are substantial. Specific strategies at preventing its occurrence are warranted, particularly in high-risk situations...
  20. ncbi request reprint Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience
    Matthew R Reynolds
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Am Heart J 145:334-42. 2003
    ..The impact of these alternative strategies on overall medical care costs is uncertain, particularly within the US health care system...
  21. doi request reprint Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction
    Kyle B Gibler
    Department of Economics, Harvard University, Cambridge, MA, USA
    Crit Pathw Cardiol 9:14-8. 2010
    ..In conclusion, this analysis finds short-term clopidogrel therapy to be a highly economically attractive therapy, improving patient outcomes at no increase in costs...
  22. ncbi request reprint An evidence-based approach to the use of drug-eluting stents in clinical practice
    Richard E Kuntz
    Division of Clinical Biometrics, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02115, USA
    Am Heart Hosp J 2:132-41. 2004
    ....
  23. doi request reprint Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events
    Michael J Rinaldi
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am Heart J 155:654-60. 2008
    ....
  24. pmc Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis
    Matthew R Reynolds
    Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am Heart J 154:1221-7. 2007
    ..Sirolimus-eluting stents (SESs) were recently shown to be superior to vascular brachytherapy for the treatment of restenosis within a bare metal stent. No economic comparison of these alternative strategies has yet been reported...
  25. ncbi request reprint Effects of stent length and lesion length on coronary restenosis
    Laura Mauri
    Division of Clinical Biometrics, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Am J Cardiol 93:1340-6, A5. 2004
    ..This analysis supports a conservative approach of matching stent length to lesion length to reduce the risk of restenosis with bare metal stents...
  26. ncbi request reprint Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent
    Dan Greenberg
    Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Z Kardiol 91:137-43. 2002
    ..S. healthcare system...
  27. ncbi request reprint Stent thrombosis after successful sirolimus-eluting stent implantation
    Allen Jeremias
    Section of Interventional Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    Circulation 109:1930-2. 2004
    ..5% to 1.9% of patients with bare metal stents. The incidence of ST with drug-eluting stents is less well studied, particularly among patients outside of clinical trials...
  28. ncbi request reprint Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy
    C Michael Gibson
    Harvard Clinical Research Institute, 900 Commonwealth Ave, 2nd Floor, Boston, MA 02215, USA
    Am Heart J 143:106-10. 2002
    ..Given the high rates of Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow after PCI, we hypothesized that abnormalities in tissue level perfusion would instead explain CK-MB release...
  29. ncbi request reprint Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative
    Adam H Skolnick
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:1790-7. 2007
    ..The goal of this work was to explore the treatment and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) age > or =90 years...
  30. ncbi request reprint Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients
    Ramon Kumar
    Department of Medicine, Cardiology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am J Cardiol 100:1187-91. 2007
    ....
  31. ncbi request reprint Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan
    J L Neumeyer
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 11:2735-40. 2001
    ..All of these novel derivatives showed a preference for the mu and kappa versus delta binding...
  32. ncbi request reprint Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial
    David J Cohen
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:1801-8. 2004
    ..The goal of this research was to determine the incremental cost and cost-effectiveness of embolic protection in patients undergoing percutaneous revascularization (PCI) of diseased saphenous vein bypass grafts (SVGs)...
  33. doi request reprint Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations
    Alexander Göhler
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Value Health 12:185-7. 2009
    ..Our objective was to estimate utilities for New York Heart Association (NYHA) classification and number of cardiovascular rehospitalizations...
  34. pmc The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators
    Matthew R Reynolds
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 47:2493-7. 2006
    ..We aimed to quantify the frequency and nature of early complications after implantable cardioverter-defibrillator (ICD) implantation in general practice, and estimate the incremental costs of those complications to the health care system...
  35. ncbi request reprint Clinical end points in coronary stent trials: a case for standardized definitions
    Donald E Cutlip
    Harvard Clinical Research Institute, Harvard Medical School, 930 Commonwealth Avenue, Boston, MA 02215, USA
    Circulation 115:2344-51. 2007
    ..Although most clinical trials of coronary stents have measured nominally identical safety and effectiveness end points, differences in definitions and timing of assessment have created confusion in interpretation...
  36. ncbi request reprint Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial
    Duane S Pinto
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:32-6. 2006
    ....
  37. pmc Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation
    Matthew R Reynolds
    Beth Israel Deaconess Medical Center, Boston, Mass 02215, USA
    Circ Arrhythm Electrophysiol 2:362-9. 2009
    ..The potential cost-effectiveness of RFA for AF, relative to antiarrhythmic drug (AAD) therapy, has not been fully explored from a US perspective...
  38. doi request reprint Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes
    Duane S Pinto
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 52:1758-68. 2008
    ..The aim of this study was to determine the economic impact of several anticoagulation strategies for moderate- and high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients managed invasively...
  39. pmc Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry
    Matthew R Reynolds
    Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA 02215, USA
    J Cardiovasc Electrophysiol 18:628-33. 2007
    ..We sought to characterize the resource utilization and costs of treating new-onset AF, with emphasis on the incremental costs associated with recurrent episodes of AF over time...
  40. pmc Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study
    Matthew R Reynolds
    Division of Cardiology, Beth Israel Deaconess Medical Center, 185 Pilgrim Road Baker 4, Boston, MA 02215, USA
    Am Heart J 152:1097-103. 2006
    ..We sought to characterize symptoms and QoL in a large inception cohort of unselected patients with AF and explore the impact of age, sex, and AF clinical course on QoL measures over time...
  41. ncbi request reprint Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials)
    Tobias T Lee
    Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 98:718-21. 2006
    ....
  42. ncbi request reprint Drug-eluting stents for ST[corrected]-elevation acute myocardial infarction: do we need randomized trials?
    Jason Ryan
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Coron Artery Dis 17:667-71. 2006
    ..In this chapter, we discuss the theoretical risks and benefits of drug-eluting stents for ST elevation acute myocardial infarction, the available data regarding their use, and the areas in which future studies are needed...
  43. ncbi request reprint Are drug-eluting stents cost-effective? It depends on whom you ask
    Jason Ryan
    Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Mass, USA
    Circulation 114:1736-43; discussion 1744. 2006
  44. ncbi request reprint Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial
    David J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:1792-800. 2004
    ..The purpose of this study was to compare the cost of percutaneous coronary intervention (PCI) using bivalirudin with provisional platelet glycoprotein (GP) IIb/IIIa inhibition with that of heparin + routine GP IIb/IIIa inhibition...
  45. doi request reprint Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs
    Matthew R Reynolds
    Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Boston, Mass, USA
    Circ Cardiovasc Qual Outcomes 3:615-23. 2010
    ..In patients with paroxysmal atrial fibrillation (AF), catheter ablation maintains sinus rhythm more effectively than antiarrhythmic drugs (AADs), but its effect on symptoms and quality of life (QOL) has not been fully characterized...
  46. ncbi request reprint Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs
    Peter Zimetbaum
    Division of Cardiology, Beth Israel Deaconess Medical Center, One Deaconess Road, Boston, MA 02215, USA
    Am J Cardiol 92:677-81. 2003
    ..We conclude that the implementation of our practice guideline was feasible, safe, and effective. Widespread adoption of such practices may have large financial implications for the health care system...
  47. ncbi request reprint Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials
    Donald E Cutlip
    Harvard Clinical Research Institute, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 40:2082-9. 2002
    ..We sought to evaluate clinical restenosis in a large population of patients who had undergone coronary stent placement...
  48. ncbi request reprint Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials
    Donald E Cutlip
    Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 110:1226-30. 2004
    ....
  49. ncbi request reprint Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial
    David J Cohen
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Mass 02215, USA
    Circulation 106:691-7. 2002
    ..Whether this practice is cost-effective is unknown...
  50. ncbi request reprint Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial
    David J Cohen
    Harvard Clinical Research Institute, Boston, Mass, USA
    Circulation 110:508-14. 2004
    ..However, the overall cost-effectiveness of this strategy is unknown...
  51. ncbi request reprint In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascuCoil Trial)
    Dan Greenberg
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Vasc Interv Radiol 15:1065-9. 2004
    ....
  52. doi request reprint Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry
    Victor Novack
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    Catheter Cardiovasc Interv 73:874-80. 2009
    ..To compare clinical outcomes in patients with and without diabetes after multivessel percutaneous coronary intervention (PCI)...
  53. ncbi request reprint Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level
    Thomas A Gaziano
    Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 112:3569-76. 2005
    ..Guidelines based on blood pressure level for initiation of treatment of hypertension may be too costly compared with an approach based on absolute cardiovascular disease (CVD) risk, especially in developing countries...
  54. ncbi request reprint Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures
    Allen Jeremias
    Harvard Clinical Research Institute, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Am Coll Cardiol 44:1210-4. 2004
    ..This study was designed to evaluate the effect of periprocedural myocardial infarction (MI) on mortality according to success of the stent procedure...
  55. doi request reprint Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model
    Pallav Garg
    Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 51:1844-53. 2008
    ..We sought to define what incremental risk of very late stent thrombosis (VLST) in drug-eluting stents (DES) would outweigh the restenosis benefit...
  56. ncbi request reprint Incidence and predictors of myocardial infarction among patients with atrial fibrillation
    P J Zimetbaum
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 36:1223-7. 2000
    ..We sought to evaluate the utility of excluding myocardial infarction (MI) in patients presenting to the emergency department (ED) with atrial fibrillation (AF) and to identify predictors of MI in this group...
  57. ncbi request reprint Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial
    Ajay J Kirtane
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, USA
    J Am Coll Cardiol 47:2374-9. 2006
    ..We aimed to identify correlates of Thrombolysis In Mycocardial Infarction (TIMI) major/minor bleeding among eptifibatide-treated patients undergoing percutaneous coronary intervention (PCI)...
  58. ncbi request reprint Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy
    Duane S Pinto
    TIMI Study Group and the Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, 185 Pilgrim Rd, Boston, MA 02115, USA
    Circulation 114:2019-25. 2006
    ..We also hypothesized that in addition to PPCI delays, patient risk factors would significantly modulate the relative survival advantage of PPCI over fibrinolysis...
  59. ncbi request reprint Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Regist
    Jason W Ryan
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 112:3049-57. 2005
    ....
  60. ncbi request reprint Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial
    S Rinfret
    Cardiovascular Data Analysis Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 38:1614-21. 2001
    ..In the absence of differences in mortality, these findings add to the overall argument in favor of initial stenting in patients treated with mechanical reperfusion for myocardial infarction...
  61. ncbi request reprint Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence
    J L Neumeyer
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Alcohol and Drug Abuse Research Center, Belmont, Massachusetts 02478 9106, USA
    J Med Chem 43:114-22. 2000
    ..Both 3a,b had comparable kappa agonist properties. 3a,b had opposing effects at the mu receptor: 3b was a mu agonist whereas 3a was a mu antagonist...
  62. ncbi request reprint Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary
    M Simons
    Angiogenesis Research Center, BIDMC, Harvard Medical School, Boston, MA, USA
    Circulation 102:E73-86. 2000
    ....
  63. ncbi request reprint Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial
    D J Cohen
    Cardiovascular Data Analysis Center, Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Circulation 104:3039-45. 2001
    ..The overall cost-effectiveness of primary stenting depends on the societal value attributed to avoidance of symptomatic restenosis, as well as on the relative mortality rates of primary PTCA and stenting...
  64. ncbi request reprint The influence of diabetes mellitus on the practice and outcomes of percutaneous coronary intervention in the community: a report from the HCA database
    Aaron D Kugelmass
    Cardiovascular Division, Henry Ford Hospital, Detroit, Michigan 48202, USA
    J Invasive Cardiol 15:568-74. 2003
    ....
  65. ncbi request reprint Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study
    Dan Greenberg
    Harvard Clinical Research Institute, Boston, MA, USA
    Health Policy 70:207-16. 2004
    ..The contingent valuation approach may offer particular advantages when evaluating treatments that improve short-term health outcomes...
  66. ncbi request reprint Practice and outcomes of percutaneous coronary intervention in the community before drug-eluting stents: a report from the HCA database
    David J Cohen
    Cardiovascular Division, Henry Ford Health System, Detroit, MI 48202, USA
    J Invasive Cardiol 15:121-7. 2003
    ..While acute clinical outcomes of the community-based PCI procedures have been examined, much less is known about long-term revascularization rates, disease progression and other adverse outcomes...
  67. ncbi request reprint Drug eluting stents for ST-elevation myocardial infarction: risk and benefit
    Jason Ryan
    Beth Israel Deaconess Medical Center and Harvard Medical School, 1 Deaconess Road, Boston, MA 02215, USA
    J Thromb Thrombolysis 24:293-9. 2007
    ..This review with discuss the theoretical risks and benefits of DES for STEMI, the available data regarding their use, and the areas where future studies are needed...
  68. ncbi request reprint A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2])
    Richard E Kuntz
    Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Am J Cardiol 89:326-30. 2002
  69. doi request reprint Deterministic sensitivity analysis for first-order Monte Carlo simulations: a technical note
    Benjamin P Geisler
    Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Value Health 12:96-7. 2009
    ..Our purpose was to facilitate one-way deterministic sensitivity analysis of TreeAge Markov state-transition models requiring first-order Monte Carlo simulations...
  70. ncbi request reprint Safety of subxyphoid pericardial access using a blunt-tip needle
    Arjuna P Mannam
    Angiogenesis Research Center, Department of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Cardiol 89:891-3. 2002
  71. ncbi request reprint The association between blood pressure and mortality in patients with heart failure
    Tobias T Lee
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Am Heart J 151:76-83. 2006
    ..Whereas many standard heart failure therapies decrease blood pressure, the relationship between mortality and blood pressure in patients with heart failure has not been previously evaluated...
  72. ncbi request reprint Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial)
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 92:779-84. 2003
    ..Hospitalizations after primary PCI are so short, however, that efforts to accelerate discharge with abciximab appear unfeasible, and overall costs remain unchanged...
  73. ncbi request reprint Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention
    J Conor O'Shea
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705
    JAMA 287:618-21. 2002
    ....
  74. doi request reprint Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'
    Allen Jeremias
    Division of Cardiovascular Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA
    Coron Artery Dis 19:111-5. 2008
    ..This study examined the performance of SES in a 'real world' setting by comparing the outcomes of trial-eligible versus ineligible patients undergoing percutaneous coronary intervention...
  75. ncbi request reprint Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial
    Stephane Rinfret
    Pharmaco economics and pharmaco epidemiology unit, Centre Hospitalier de l Universite de Montreal CHUM, Montreal, Quebec, Canada
    Am J Cardiovasc Drugs 6:159-68. 2006
    ..The cost effectiveness of drug-eluting stents in Canada is debated and deserves further evaluation in high-risk patients...
  76. ncbi request reprint Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry
    John A Spertus
    MPH, Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111
    Circulation 113:2803-9. 2006
    ..The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown...
  77. ncbi request reprint Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:1585-90. 2006
    ..A randomized trial comparing multivessel PCI with staged or surgical revascularization is warranted...
  78. ncbi request reprint Does stenting save lives? Understanding the strengths and limitations of meta-analysis
    Adhir R Shroff
    Am Heart J 147:756-8. 2004
  79. ncbi request reprint Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 292:696-703. 2004
    ....
  80. ncbi request reprint Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial
    Matthews Chacko
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:1032.e1-7. 2006
    ..The REPLACE-2 trial demonstrated that bivalirudin with provisional glycoprotein IIb/IIIa (GpIIb-IIIa) blockade is noninferior to heparin with planned GpIIb-IIIa blockade during PCI, with regard to ischemic and bleeding end points...
  81. ncbi request reprint Hospital resources consumed in treating complications associated with percutaneous coronary interventions
    Aaron D Kugelmass
    The Cardiovascular Division, Henry Ford Hospital, Detroit, Michigan, USA
    Am J Cardiol 97:322-7. 2006
    ..In conclusion, we found that the incremental hospital resources that are consumed to treat patients with acute PCI complications are large compared with the cost of an uncomplicated PCI hospitalization...
  82. ncbi request reprint Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)
    Derek P Chew
    Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia
    Am J Cardiol 95:581-5. 2005
    ..The safety and efficacy of bivalirudin compared with heparin and planned glycoprotein IIb/IIIa inhibition in this high-risk group are comparable and consistent with the results of the overall trial...
  83. ncbi request reprint Conducting economic evaluations alongside multinational clinical trials: toward a research consensus
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
    Am Heart J 149:434-43. 2005
    ..Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies...
  84. ncbi request reprint Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data
    Mary Ann Clark
    Department of Health Economics and Outcomes Research, Boston Scientific Corporation, Natick, Mass, USA
    Circulation 110:259-64. 2004
    ..Outcomes after percutaneous coronary intervention (PCI) have been documented extensively in clinical trials and single-center series, but few data exist on the clinical and economic outcomes after PCI in an unselected population...
  85. ncbi request reprint Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 289:853-63. 2003
    ....
  86. ncbi request reprint Protected carotid stenting in high-surgical-risk patients: the ARCHeR results
    William A Gray
    Columbia University Medical Center, New York, NY 10032, USA
    J Vasc Surg 44:258-68. 2006
    ....
  87. ncbi request reprint Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    JAMA 297:591-602. 2007
    ..The preferred approach is undetermined...
  88. ncbi request reprint Resource utilization, cost, and health status impacts of coronary stent versus "optimal" percutaneous coronary angioplasty: results from the OPUS-I trial
    Nancy Neil
    Virginia Mason Medical Center, University of Washington School of Public Health, Seattle, Washington
    J Interv Cardiol 15:249-55. 2002
    ....
  89. ncbi request reprint Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial
    Vivek Rajagopal
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:149-54. 2006
    ..Therefore, we sought to determine if bivalirudin has similar efficacy in ACS patients as compared with "stable" patients in the REPLACE-2 trial...
  90. ncbi request reprint Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial
    Gregg W Stone
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY 10022, USA
    Circulation 105:2347-54. 2002
    ..Also unknown is whether the acuity of the presenting clinical syndrome, which may affect the degree of platelet inhibition required or achieved, influences the response to different antiplatelet agents...
  91. ncbi request reprint Impact of the Food and Drug Administration's Public Health Notification on the adoption of drug-eluting stents
    Jeptha P Curtis
    Yale University, New Haven, Connecticut, USA
    Am J Cardiol 99:1227-9. 2007
    ..By January 2004, DES use had returned to the prenotification rate and continued to increase thereafter. In conclusion, the Food and Drug Administration's notification had a modest but temporary effect on clinical practice...
  92. ncbi request reprint Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial
    Christopher J Cooper
    Department of Medicine, Medical University of Ohio, Toledo, OH 43614 2598, USA
    Am Heart J 152:59-66. 2006
    ..Whether revascularization improves clinical outcomes when compared with optimum medical therapy is unknown...
  93. ncbi request reprint Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents
    Htut K Win
    Baylor College of Medicine, Houston, Tex USA
    JAMA 297:2001-9. 2007
    ..The degree to which they experience cardiac events at a higher rate than non-high-risk patients is unclear...
  94. ncbi request reprint Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEG
    Marco Valgimigli
    Cardiology, University of Ferrara, Ferrara, Italy
    Am Heart J 154:39-45. 2007
    ..Similarly, whether tirofiban administered at high-bolus dose (HBD) followed by standard infusion is a valuable alternative to abciximab in the setting of ST-segment elevation myocardial infarction remains uncertain...
  95. ncbi request reprint A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction
    Marco Valgimigli
    Cardiovascular Institute, University of Ferrara, Ferrara, Italy
    Int J Cardiol 128:53-61. 2008
    ....
  96. ncbi request reprint Vascular closure devices: the second decade
    Harold L Dauerman
    Division of Cardiology, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
    J Am Coll Cardiol 50:1617-26. 2007
    ..Challenges in the second decade of VCD experience will include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing more ideal closure devices...